Large artery stiffness and hypertension after antiangiogenic drugs: influence on cancer progression
暂无分享,去创建一个
[1] P. Challande,et al. Smooth Muscle Cell Mineralocorticoid Receptors Are Mandatory for Aldosterone–Salt to Induce Vascular Stiffness , 2014, Hypertension.
[2] L. Ferrucci,et al. Longitudinal Trajectories of Arterial Stiffness and the Role of Blood Pressure: The Baltimore Longitudinal Study of Aging , 2013, Hypertension.
[3] Stéphane Laurent,et al. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. , 2013, European heart journal.
[4] Masataka Nakano,et al. Pathophysiology of atherosclerosis plaque progression. , 2013, Heart, lung & circulation.
[5] R. Jain. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Sledge,et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. , 2013, The oncologist.
[7] H. Nakajima,et al. Aortic dissection in the outer third of the media: what is the role of the vasa vasorum in the triggering process? , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[8] Michael J Thun,et al. 50-year trends in smoking-related mortality in the United States. , 2013, The New England journal of medicine.
[9] L. Berry. Better long-term support needed to cut cancer deaths. , 2012, Nursing older people.
[10] Daniel Levy,et al. Aortic stiffness, blood pressure progression, and incident hypertension. , 2012, JAMA.
[11] R. Pazdur,et al. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. , 2012, The Oncologist.
[12] A. Koller,et al. Contribution of Flow-Dependent Vasomotor Mechanisms to the Autoregulation of Cerebral Blood Flow , 2012, Journal of Vascular Research.
[13] S. Sleijfer,et al. Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress , 2012, Hypertension.
[14] Bertrand Knebelmann,et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. , 2011, The oncologist.
[15] S. Laurent,et al. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients , 2010, Journal of hypertension.
[16] Rakesh K. Jain,et al. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.
[17] O. Mir,et al. Treatment of bevacizumab-induced hypertension by amlodipine , 2012, Investigational New Drugs.
[18] T. Choueiri,et al. Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors , 2010, Hypertension.
[19] P. Carmeliet,et al. Vascular Endothelial Growth Factor-B Acts as a Coronary Growth Factor in Transgenic Rats Without Inducing Angiogenesis, Vascular Leak, or Inflammation , 2010, Circulation.
[20] S. Sleijfer,et al. Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels , 2010, Hypertension.
[21] Yunhe Jia,et al. Anti-angiogenesis therapies: their potential in cancer management , 2010, OncoTargets and therapy.
[22] Yasmin,et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’ , 2010, European heart journal.
[23] Stéphane Laurent,et al. Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination: The EXPLOR Study , 2010, Hypertension.
[24] T. Choueiri,et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Thomas H Marwick,et al. Augmentation Index, Left Ventricular Contractility, and Wave Reflection , 2009, Hypertension.
[26] M. Maitland,et al. Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment , 2009, Clinical Cancer Research.
[27] C. Pournaras,et al. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. , 2009, Ophthalmology.
[28] Stéphane Laurent,et al. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. , 2009, Hypertension.
[29] K. Stergiopoulos,et al. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis , 2009, Acta oncologica.
[30] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[31] O. Bouché,et al. [Vascular and renal effects of anti-angiogenic therapy]. , 2008, Nephrologie & therapeutique.
[32] P. Rieu,et al. [Vascular and renal effects of anti-angiogenic therapy]. , 2008, Nephrologie & therapeutique.
[33] B. Lévy,et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] E. Raymond,et al. New developments in multitargeted therapy for patients with solid tumours. , 2008, Cancer treatment reviews.
[35] A. Kudelka,et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. , 2008, The Lancet. Oncology.
[36] S. Oudard,et al. Home blood-pressure monitoring in patients receiving sunitinib. , 2008, The New England journal of medicine.
[37] David Zurakowski,et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.
[38] P. Bärtsch,et al. Effect of altitude on the heart and the lungs. , 2007, Circulation.
[39] P. Challande,et al. Role of α1β1-integrin in arterial stiffness and angiotensin-induced arterial wall hypertrophy in mice , 2007 .
[40] P. Challande,et al. Role of alpha1beta1-integrin in arterial stiffness and angiotensin-induced arterial wall hypertrophy in mice. , 2007, American journal of physiology. Heart and circulatory physiology.
[41] H. Struijker‐Boudier,et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. , 2006, European heart journal.
[42] D. Calvet,et al. Carotid and Aortic Stiffness: Determinants of Discrepancies , 2006, Hypertension.
[43] Stéphane Laurent,et al. Structural and Genetic Bases of Arterial Stiffness , 2005, Hypertension.
[44] W. Nichols. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. , 2005, American journal of hypertension.
[45] Stéphane Laurent,et al. Increased Carotid Wall Stress in Vascular Ehlers-Danlos Syndrome , 2004, Circulation.
[46] Arnold P G Hoeks,et al. Simultaneous assessment of diameter and pressure waveforms in the carotid artery. , 2004, Ultrasound in medicine & biology.
[47] D. Sane,et al. Angiogenic growth factors and hypertension , 2004, Angiogenesis.
[48] E L Ritman,et al. Impact of coronary vasa vasorum functional structure on coronary vessel wall perfusion distribution. , 2003, American journal of physiology. Heart and circulatory physiology.
[49] D P Sokolis,et al. Effect of impaired vasa vasorum flow on the structure and mechanics of the thoracic aorta: implications for the pathogenesis of aortic dissection. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[50] C. Vlachopoulos,et al. Effect of vasa vasorum flow on structure and function of the aorta in experimental animals. , 1995, Circulation.
[51] C. Vlachopoulos,et al. Medial necrosis and acute alterations in aortic distensibility following removal of the vasa vasorum of canine ascending aorta. , 1993, Cardiovascular research.
[52] D. Greene,et al. In vitro correction of impaired Na+-K+-ATPase in diabetic nerve by protein kinase C agonists. , 1989, The American journal of physiology.
[53] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.